- Home
- ABLV vs IFRX Comparison
ABLV vs IFRX Comparison
Compare ABLV & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABLV
- IFRX
- Stock Information
- Founded
- ABLV 2015
- IFRX 2007
- Country
- ABLV China
- IFRX Germany
- Employees
- ABLV N/A
- IFRX N/A
- Industry
- ABLV
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- ABLV
- IFRX Health Care
- Exchange
- ABLV Nasdaq
- IFRX Nasdaq
- Market Cap
- ABLV 51.4M
- IFRX 53.5M
- IPO Year
- ABLV N/A
- IFRX 2017
- Fundamental
- Price
- ABLV $0.92
- IFRX $1.46
- Analyst Decision
- ABLV
- IFRX Strong Buy
- Analyst Count
- ABLV 0
- IFRX 5
- Target Price
- ABLV N/A
- IFRX $7.40
- AVG Volume (30 Days)
- ABLV 20.0K
- IFRX 740.6K
- Earning Date
- ABLV 12-19-2025
- IFRX 11-07-2025
- Dividend Yield
- ABLV N/A
- IFRX N/A
- EPS Growth
- ABLV N/A
- IFRX N/A
- EPS
- ABLV 0.05
- IFRX N/A
- Revenue
- ABLV $114,319,869.00
- IFRX $191,224.00
- Revenue This Year
- ABLV N/A
- IFRX N/A
- Revenue Next Year
- ABLV N/A
- IFRX $1,216.24
- P/E Ratio
- ABLV $19.45
- IFRX N/A
- Revenue Growth
- ABLV N/A
- IFRX 54.36
- 52 Week Low
- ABLV $0.55
- IFRX $0.71
- 52 Week High
- ABLV $1.77
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- ABLV 46.13
- IFRX 54.12
- Support Level
- ABLV $0.88
- IFRX $1.30
- Resistance Level
- ABLV $0.98
- IFRX $1.71
- Average True Range (ATR)
- ABLV 0.07
- IFRX 0.16
- MACD
- ABLV -0.01
- IFRX 0.00
- Stochastic Oscillator
- ABLV 16.04
- IFRX 56.90
About ABLV Able View Global Inc.
Able View Global Inc operates as a brand management partner of international beauty and personal care brands in China. It provides full-service solutions covering marketing plan, branding, digital and social marketing, omni-channel sales, customer service, overseas logistics, warehouse, and fulfillment. The firm generates revenue from product sales by distributing and selling cross-border products from various brand owners to Chinese consumers.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.